2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·32 min sittenSurely several here who hold non-listed shares in SOW after the split last year. Does anyone know what happens to these shares now that they are to be transferred to the new AB company? It's probably only some selected large shareholders who are invited to transfer the shares according to IM. So what happens to the rest? https://sow.no/investor-information/
·58 min sittenI have such a good feeling about this stock! I have studied the company and its development carefully. There is potential for enormous price growth in the stock if the next study proves successful and gets approved. It is now being tested on humans and the first results should appear in the near future. Financing from Long State would not have been so relevant and would not have been used so frequently if they didn't also believe they would get their money back with a very nice profit. These are large sums we're talking about, and I think all parties involved are not here to "play games". I'm staying put and hope this will give me a nice chunk of holiday money. Good luck to all SoftOx`ers😉👏
·7 min sitten · MuokattuEager for the first topline data from the phase 2a study, it shows signs of reduction of bacteria in the lungs. So I believe the rocket flies far. What is even more exciting is if the cystic fibrosis bacteria show signs of reduction is that these often can become antibiotic resistant due to biofilm
·15 t sittenWhat do we think em Softox for the rest of 2026 Vs Circio?
·9 t sittenSoftOx starts a Phase 2a study with their inhalation medicine for chronic lung diseases. • The study starts in Q1 2026 • The first dose results are expected in the first half of 2026  👉 If the results are good: • the share can rise sharply (typically 100-500 % in small biotech). 👉 If the results are bad: • the share can fall a lot.
·17 t sittenJust for info after new shareholder lists were published today Can this be big news ? Someone who bought large quantities of shares 1. PATIAS INNOVATION AS +16 250 000 ↑ 0,6672% 16 250 000 0,67% info about the Company and owner ; Key information about the company: Owner: Pål Rongved Organization number: 925 201 332. Business: The company is engaged in research and development within medicine, with a focus on technologies against virus pandemics and resistance issues. He is also a board member in a company named AdjuTec Pharma AS Possible collaboration ?
·12 t sittenThat he has come in is very BULL. He has rich friends. https://www.researchgate.net/profile/Pal-Rongved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·32 min sittenSurely several here who hold non-listed shares in SOW after the split last year. Does anyone know what happens to these shares now that they are to be transferred to the new AB company? It's probably only some selected large shareholders who are invited to transfer the shares according to IM. So what happens to the rest? https://sow.no/investor-information/
- ·58 min sittenI have such a good feeling about this stock! I have studied the company and its development carefully. There is potential for enormous price growth in the stock if the next study proves successful and gets approved. It is now being tested on humans and the first results should appear in the near future. Financing from Long State would not have been so relevant and would not have been used so frequently if they didn't also believe they would get their money back with a very nice profit. These are large sums we're talking about, and I think all parties involved are not here to "play games". I'm staying put and hope this will give me a nice chunk of holiday money. Good luck to all SoftOx`ers😉👏·7 min sitten · MuokattuEager for the first topline data from the phase 2a study, it shows signs of reduction of bacteria in the lungs. So I believe the rocket flies far. What is even more exciting is if the cystic fibrosis bacteria show signs of reduction is that these often can become antibiotic resistant due to biofilm
- ·15 t sittenWhat do we think em Softox for the rest of 2026 Vs Circio?·9 t sittenSoftOx starts a Phase 2a study with their inhalation medicine for chronic lung diseases. • The study starts in Q1 2026 • The first dose results are expected in the first half of 2026  👉 If the results are good: • the share can rise sharply (typically 100-500 % in small biotech). 👉 If the results are bad: • the share can fall a lot.
- ·17 t sittenJust for info after new shareholder lists were published today Can this be big news ? Someone who bought large quantities of shares 1. PATIAS INNOVATION AS +16 250 000 ↑ 0,6672% 16 250 000 0,67% info about the Company and owner ; Key information about the company: Owner: Pål Rongved Organization number: 925 201 332. Business: The company is engaged in research and development within medicine, with a focus on technologies against virus pandemics and resistance issues. He is also a board member in a company named AdjuTec Pharma AS Possible collaboration ?·12 t sittenThat he has come in is very BULL. He has rich friends. https://www.researchgate.net/profile/Pal-Rongved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
106 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·32 min sittenSurely several here who hold non-listed shares in SOW after the split last year. Does anyone know what happens to these shares now that they are to be transferred to the new AB company? It's probably only some selected large shareholders who are invited to transfer the shares according to IM. So what happens to the rest? https://sow.no/investor-information/
- ·58 min sittenI have such a good feeling about this stock! I have studied the company and its development carefully. There is potential for enormous price growth in the stock if the next study proves successful and gets approved. It is now being tested on humans and the first results should appear in the near future. Financing from Long State would not have been so relevant and would not have been used so frequently if they didn't also believe they would get their money back with a very nice profit. These are large sums we're talking about, and I think all parties involved are not here to "play games". I'm staying put and hope this will give me a nice chunk of holiday money. Good luck to all SoftOx`ers😉👏·7 min sitten · MuokattuEager for the first topline data from the phase 2a study, it shows signs of reduction of bacteria in the lungs. So I believe the rocket flies far. What is even more exciting is if the cystic fibrosis bacteria show signs of reduction is that these often can become antibiotic resistant due to biofilm
- ·15 t sittenWhat do we think em Softox for the rest of 2026 Vs Circio?·9 t sittenSoftOx starts a Phase 2a study with their inhalation medicine for chronic lung diseases. • The study starts in Q1 2026 • The first dose results are expected in the first half of 2026  👉 If the results are good: • the share can rise sharply (typically 100-500 % in small biotech). 👉 If the results are bad: • the share can fall a lot.
- ·17 t sittenJust for info after new shareholder lists were published today Can this be big news ? Someone who bought large quantities of shares 1. PATIAS INNOVATION AS +16 250 000 ↑ 0,6672% 16 250 000 0,67% info about the Company and owner ; Key information about the company: Owner: Pål Rongved Organization number: 925 201 332. Business: The company is engaged in research and development within medicine, with a focus on technologies against virus pandemics and resistance issues. He is also a board member in a company named AdjuTec Pharma AS Possible collaboration ?·12 t sittenThat he has come in is very BULL. He has rich friends. https://www.researchgate.net/profile/Pal-Rongved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt